A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
Status:
Terminated
Trial end date:
2019-07-20
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label study for eligible participants who were actively
participating in the BPS-314d-MR-PAH-302 double-blind study (NCT01908699) at the time the
study was concluded. This open-label extension (OLE) study will evaluate the safety,
tolerability, and efficacy of long-term treatment with esuberaprost sodium tablets (Beraprost
Sodium 314d Modified Release tablets).